ClinicalTrials.gg
Not yet recruitingNCT05949424OPTI-DOSEUpdated Nov 29, 2023

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

A Phase 4 interventional study of Olaparib and Lenvatinib in Renal Cell Carcinoma, Ovarian Carcinoma and Thyroid Carcinoma, sponsored by University Medical Center Groningen. Not yet recruiting at 1 site in Netherlands. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by University Medical Center Groningen · Phase 4, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing lenvatinib in Carcinoma, Renal Cell — 13 open to participants now, 17 under way, 2 of them phase 3. lenvatinib · Carcinoma, Renal Cell.

Planned enrollment
15th of 30
30 · median 30
Started
2024
with 1 other
Phase 4
Only one
of the 30
Primary completion
2025-03
later than 2 of 16 live
Registered
16th of 30
by date

Among the 30 studies testing lenvatinib in Carcinoma, Renal Cell, this one is the 15th largest by planned enrollment, is one of 2 that started in 2024, is the only one in phase 4, reaches primary completion later than 2 of the 16 other live ones, and was the 16th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

13 of the 30 studies testing lenvatinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing lenvatinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same. The trial population consists of 30 patients aged 65 years or older, who are starting treatment with one of these anti cancer tablet treatments: pazopanib, olaparib, lenvatinib, sunitinib or palbociclib. The control group (half of the participants) will be treated with the standard-of-care, the interventional group will start with the lowest dose of the anti cancer tablets as described in the drug label. The dose will be increased every two weeks in case of good tolerability. Results of this pilot study will be used to inform the design of the larger randomised phase 2 trial.

Read the detailed description

Information about the benefits and side effects of treatments for cancer is mainly derived from studies with younger patients. It is known that elderly patients experience more side effects from treatments, which can lead to a worse quality of life. The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same.

The trial population consists of 30 patients aged 65 years or older, who are starting treatment with one of these anti cancer tablet treatments: pazopanib, olaparib, lenvatinib, sunitinib or palbociclib. This is a randomized study with 1:1 randomisation, stratified by type of anti-cancer treatment.

The control group (half of the participants) will be treated with the standard-of-care, that means with the recommended starting dose of the anti cancer tablets as described in the drug label. The dose can be adjusted (lowered) if this is necessary, for example because of side effects, based on the judgment of the treating physician. The interventional group (half of the participants) will start with the lowest dose of the anti cancer tablets as described in the drug label. The dose will be increased every two weeks in case of good tolerability. Results of this pilot study will be used to inform the design of the larger randomised phase 2 trial, for example the primary endpoint, the amount of investigations and the size of the study population.

Study visits are planned every 2 weeks for a total study duration of 12 weeks, the time point for analysis of the primary endpoint. Blood samples for PK analysis are collected every 2 weeks. A baseline blood sample will be collected for pharmacogenomic analysis.

03

Conditions studied

  • Renal Cell Carcinoma
  • Ovarian Carcinoma
  • Thyroid Carcinoma
  • Breast Carcinoma
  • Endometrium Carcinoma
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients ≥ 65 years of age.
  • Indication for starting treatment with pazopanib (for renal cell carcinoma), olaparib (for ovarian carcinoma), lenvatinib (as monotherapy for thyroid carcinoma, or in combination with pembrolizumab for renal cell carcinoma or endometrium carcinoma), sunitinib (for renal cell carcinoma) or palbociclib (for breast carcinoma).
  • No for starting treatment at the recommended starting dose as per SmPC.
  • All patients must provide written prior to enrolment.

Exclusion criteria

Exclusion Criteria:

  • Planned starting dose lower than the recommended starting dose as per SmPC

For Pazopanib:

  • Use of a strong -inhibitor or PgP-inhibitor
  • \<30ml/min
  • Moderate or severe hepatic impairment ( >1.5x )

For Olaparib:

  • Use of a moderate or strong CYP3A4-inhibitor
  • Creatinine clearance \<50 ml/min
  • Severe hepatic impairment ( 10-15)

For Lenvatinib:

  • Creatinine clearance \<30ml/min
  • Severe hepatic impairment (Child-Pugh score 10-15)

For Sunitinib:

  • Use of a strong CYP3A4-inhibitor
  • Use of a strong CYP3A4-inducer

For Palbociclib:

  • Use of a strong CYP3A4-inhibitor
  • Severe hepatic impairment (Child-Pugh score 10-15)
  • Other findings at interview or physical examination that hamper compliance to the study protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Control group

    Standard SmPC dosing with dose adjustments for toxicity as per SmPC

    Drug: Olaparib · Drug: Lenvatinib · Drug: Sunitinib · Drug: Palbociclib · Drug: Pazopanib

  • Experimental
    Intervention group

    Lower starting dose with dose-escalation inversely following the dosing steps from the SmPC every 2 weeks in case of good tolerability

    Drug: Olaparib · Drug: Lenvatinib · Drug: Sunitinib · Drug: Palbociclib · Drug: Pazopanib

Interventions

  • Starting dose of 200mg 2dd.

    Also known as: Lynparza

  • Starting dose of 10mg 1dd.

    Also known as: Lenvima

  • Starting dose of 25mg 1dd 28/42 days.

    Also known as: Sutent

  • Starting dose of 75mg 1dd 21/28 days.

    Also known as: Ibrance

  • Starting dose of 200mg 1dd.

    Also known as: Votrient

  • Starting dose of 300mg 2dd.

    Also known as: Lynparza

  • Starting dose of 20mg 1dd for RCC or endometrial carcinoma, starting dose of 24mg 1dd for thyroid carcinoma.

    Also known as: Lenvima

  • Starting dose of 50mg 1dd 28/42 days.

    Also known as: Sutent

  • Starting dose of 125mg 1dd 21/28 days.

    Also known as: Ibrance

  • Starting dose of 800mg 1dd.

    Also known as: Votrient

06

What researchers measure

Primary outcomes

  1. Feasibility of investigating whether a lower starting dose with step-up approach leads to a better overall treatment utility compared to standard dosing

    * The percentage of patients that are willing to participate, from all eligible patients * The percentage of patients that successfully complete the first 12 weeks of the trial * The percentage of data points that are successfully collected during the first 12 weeks of the trial

    Time frame: 12 weeks

Secondary outcomes

  1. Overall treatment utility

    measured by the investigator. See: https://blogs.ed.ac.uk/canceroutcomes/overall-treatment-utility/#:\~:text=In%20Oncology%20clinical%20research%2C%20Overall%20Treatment%20Utility%20%28OTU%29,balance%20of%20benefits%20and%20harms%20from%20cancer%20treatments

    Time frame: 12 weeks

  2. Progression free survival

    From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

    Time frame: up to 60 months

  3. Overall survival

    From date of randomization until the date of death from any cause, assessed up to 60 months

    Time frame: up to 60 months

  4. Quality of life

    measured by QLQ-C30 (general) and QLQ-ELD14 (elderly cancer patients)

    Time frame: 12 weeks

  5. Safety

    Adverse events, measured by CTCAE v5.0

    Time frame: 12 weeks

  6. Hospital care use

    number of outpatients visits, telephone contacts or hospital admission days

    Time frame: 12 weeks

  7. Pharmacokinetic parameters: Cmax

    Peak Plasma Concentration (Cmax)

    Time frame: 12 weeks

  8. Pharmacokinetic parameters: AUC

    Area under the plasma concentration versus time curve (AUC)

    Time frame: 12 weeks

  9. Pharmacokinetic parameters: Ctrough

    Trough Plasma Concentration (Ctrough)

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for Mar 2025, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2023
First posted
Jul 18, 2023
StartEst.
May 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2025
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05949424
Responsible party
Sponsor
First posted
Jul 18, 2023
Start date
May 2024 (estimated)
Primary completion
Mar 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Nov 29, 2023

Study contacts

Esther Broekman, MD
Contact
k.e.broekman@umcg.nl
+31 50 361 0841
Esther Broekman, MD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Olaparib · Lenvatinib · Sunitinib · Palbociclib · Pazopanib

Start the discussion